Zydus Lifesciences Resolves Mirabegron Patent Litigation with Astellas for $120 Million

, along with its U.S. subsidiary, has agreed to pay Astellas Pharma $120 million to settle ongoing patent infringement disputes over the bladder disorder treatment Mirabegron. This deal, announced on February 12, 2026, also includes prepaid per-unit licensing fees on U.S. sales of Zydus's generic version from the agreement date through September 2027. The settlement permits Zydus to maintain its generic Mirabegron marketing in the U.S. market without further legal interruptions, with additional terms kept confidential. It follows a similar resolution by competitor Lupin Ltd., which paid $90 million for the same drug, potentially limiting near-term generic entry and favoring early settlers. Disclaimer: This post is for informational purposes only and not a recommendation to buy or sell any securities. I, or my family, associates, or relatives, may have a financial interest in the securities mentioned.